Immucell (ICCC) Revenue (2010 - 2026)
Immucell's (ICCC) quarterly Revenue came in at $7.6 million in Q4 2025, down 1.61% YoY from $7.8 million in Q4 2024, and up 38.5% on a QoQ basis from $5.5 million in Q3 2025.
Immucell (ICCC) Revenue (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Revenue data on file, last reported at $7.6 million in Q4 2025.
- Quarterly Revenue fell 1.61% year-over-year to $7.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.6 million (up 31.14% YoY) and the FY2025 annual result came in at $27.6 million, up 4.34% from the prior year.
- Revenue improved to $7.6 million in Q4 2025, from $5.5 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $8.1 million in Q1 2025 to a low of $60229.0 in Q2 2024.
- A 5-year average of $5.2 million and a median of $5.4 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2024 — Revenue sank 98.3% — and 2025, when it surged 10600.63%.
- Tracing ICCC's Revenue over 5 years: stood at $5.4 million in 2021, then fell by 28.16% to $3.9 million in 2022, then soared by 37.99% to $5.4 million in 2023, then surged by 43.63% to $7.8 million in 2024, then declined by 1.61% to $7.6 million in 2025.
- The last three Revenue figures came in at $7.6 million (Q4 2025), $5.5 million (Q3 2025), and $6.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | 7.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.19 Mn |
| Dec 31, 2025 | 7.63 Mn |
| Sep 30, 2025 | 5.51 Mn |
| Jun 30, 2025 | 6.44 Mn |
| Mar 31, 2025 | 8.07 Mn |
| Dec 31, 2024 | 7.75 Mn |
| Sep 30, 2024 | 6.01 Mn |
| Jun 30, 2024 | 60,229.00 |
| Mar 31, 2024 | 7.26 Mn |
| Sep 30, 2023 | 5.40 Mn |
| Jun 30, 2023 | 3.53 Mn |
| Mar 31, 2023 | 3.45 Mn |
| Dec 31, 2022 | 3.91 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Jun 30, 2022 | 3.86 Mn |
| Mar 31, 2022 | 6.00 Mn |
| Dec 31, 2021 | 5.44 Mn |
| Sep 30, 2021 | 5.15 Mn |
| Jun 30, 2021 | 4.54 Mn |
| Mar 31, 2021 | 4.11 Mn |